Elevated ITGAV Expression in Seropositive Rheumatoid Arthritis: Diagnostic Potential and Immunopathological Insights

Area of Science:

• Immunology
• Rheumatology
• Biomarker Discovery

Background:

• Rheumatoid arthritis (RA) is a chronic autoimmune disease causing joint inflammation and destruction.
• Current diagnostic methods for RA lack sufficient sensitivity for early detection.
• There is a critical need for reliable biomarkers for early RA diagnosis and stratification.

Purpose of the Study:

• To investigate integrin alpha V (ITGAV) as a potential diagnostic biomarker for rheumatoid arthritis.
• To assess the correlation of ITGAV expression with clinical and serological parameters in RA patients.
• To explore the diagnostic performance of ITGAV using receiver operating characteristic (ROC) curve analysis.

Main Methods:

• Quantification of ITGAV expression in peripheral blood samples from RA patients, osteoarthritis patients, and healthy controls using ELISA.
• Correlation analysis of ITGAV levels with clinical parameters (serological markers, ultrasound scores, disease activity indices).
• Analysis of transcriptomic and single-cell RNA sequencing data to identify ITGAV expression in immune cell subsets; ROC curve analysis for diagnostic accuracy.

Main Results:

• ITGAV levels were significantly higher in RA patients, especially those seropositive for rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies.
• ITGAV expression correlated positively with RF and anti-CCP titres.
• Single-cell analysis showed ITGAV enrichment in pro-inflammatory macrophages and T cells, with positive association to synovial thickness; ROC analysis indicated high diagnostic accuracy (AUC > 0.96).

Conclusions:

• Integrin alpha V (ITGAV) is upregulated in seropositive RA, demonstrating potential as a non-invasive biomarker for diagnosis and stratification.
• ITGAV's expression in inflammatory immune cells and association with synovial inflammation suggest its role in RA pathogenesis.
• Further studies are needed to validate ITGAV's utility in personalized RA management.